Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI

Published: 01 September 2020

  • Views:

    Views Icon 1483
  • Likes:

    Heart Icon 7
  • episode_image
    Now Playing
    Part 1 | Session 1 of 1
    Welcome
    Kurt Huber
    Up Next
  • episode_image
    Part 5 | Session 1 Q&As
    Kurt Huber, Davide Capodanno, Stefan James, Roxana Mehran

Overview

In this series of videos Kurt Huber, Davide Capodanno, Stefan James and Roxana Mehran discuss Navigating the Antithrombotic Maze: What to do for Your ACS Patients in the Era of Contemporary PCI

Supported by an unrestricted educational grant from AstraZeneca

Learning Objectives

  • Review the clinical landscape for antiplatelet therapy in patients with ACS.
  • Discuss recent data on DAPT for patients with ACS
  • Provide expert insight on application in routine clinical practice

More from this programme

Part 1

Welcome

1 session
Welcome Watch now

Part 2

Pre-treatment in NSTE-ACS – Dead or Alive?

Part 3

Choice of Antithrombotic Agent in ACS: REACT-ing to Recent Trials

Part 4

When to leave Aspirin behind?

Part 5

Q&As

1 session
Q&As Watch now

Faculty Biographies

Kurt Huber

Kurt Huber

Head of the 3rd Med. Dept. of Cardiology and Internal Intensive Care Medicine

Prof Kurt Huber is Head of the 3rd Med. Dept. with Cardiology and Internal Intensive Care Medicine at the Clinic Ottakring, Vienna.

Prof Huber is an interventional cardiologist with over 35 years of experience. His main research interest covers basic research (mechanisms of thrombus formation and dissolution) as well as clinical research (acute coronary syndromes, organization of STEMI networks, antithrombotic therapy in CV diseases).

View full profile